Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis

NCT07636057 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: JAK inhibitor(tofacitinib/upadacitinib) as advised by the rheumatologist as add on to 25 mg methotrexate

Sponsor

Sheikh Zayed Federal Postgraduate Medical Institute